Hollsteen
← KLA

Equity incl. NCI

Balance – as of period end · $M

QuartersFiscal years

$MEquity incl. NCI · Q1 FY2016: $294M · 10-Q 0000319201-15-000060 filed Oct 22, 2015Equity incl. NCI · Q2 FY2016: $366M · 10-Q 0000319201-16-000065 filed Jan 28, 2016Equity incl. NCI · Q3 FY2016: $477M · 10-Q 0000319201-16-000077 filed Apr 26, 2016Equity incl. NCI · Q4 FY2016: $689M · 10-K 0000319201-16-000090 filed Aug 5, 2016Equity incl. NCI · Q1 FY2017: $782M · 10-Q 0000319201-16-000104 filed Oct 20, 2016Equity incl. NCI · Q2 FY2017: $965M · 10-Q 0000319201-17-000006 filed Jan 27, 2017Equity incl. NCI · Q3 FY2017: $1.1B · 10-Q 0000319201-17-000017 filed Apr 28, 2017Equity incl. NCI · Q4 FY2017: $1.3B · 10-K 0000319201-17-000034 filed Aug 4, 2017Equity incl. NCI · Q1 FY2018: $1.5B · 10-Q 0000319201-17-000045 filed Oct 27, 2017Equity incl. NCI · Q2 FY2018: $1.2B · 10-Q 0000319201-18-000008 filed Jan 26, 2018Equity incl. NCI · Q3 FY2018: $1.4B · 10-Q 0000319201-18-000021 filed Apr 27, 2018Equity incl. NCI · Q4 FY2018: $1.6B · 10-K 0000319201-18-000045 filed Aug 6, 2018Equity incl. NCI · Q1 FY2019: $1.6B · 10-Q 0000319201-18-000055 filed Oct 31, 2018Equity incl. NCI · Q2 FY2019: $1.6B · 10-Q 0000319201-19-000009 filed Jan 29, 2019Equity incl. NCI · Q3 FY2019: $2.9B · 10-Q 0000319201-19-000018 filed May 8, 2019Equity incl. NCI · Q4 FY2019: $2.7B · 10-K 0000319201-19-000031 filed Aug 16, 2019Equity incl. NCI · Q1 FY2020: $2.7B · 10-Q 0000319201-19-000039 filed Oct 31, 2019Equity incl. NCI · Q2 FY2020: $2.7B · 10-Q 0000319201-20-000008 filed Feb 5, 2020Equity incl. NCI · Q3 FY2020: $2.3B · 10-Q 0000319201-20-000026 filed May 6, 2020Equity incl. NCI · Q4 FY2020: $2.7B · 10-K 0000319201-20-000047 filed Aug 10, 2020Equity incl. NCI · Q1 FY2021: $2.8B · 10-Q 0000319201-20-000057 filed Oct 30, 2020Equity incl. NCI · Q2 FY2021: $3.0B · 10-Q 0000319201-21-000008 filed Feb 4, 2021Equity incl. NCI · Q3 FY2021: $3.1B · 10-Q 0000319201-21-000017 filed Apr 30, 2021Equity incl. NCI · Q4 FY2021: $3.4B · 10-K 0000319201-21-000029 filed Aug 6, 2021Equity incl. NCI · Q1 FY2022: $3.9B · 10-Q 0000319201-21-000037 filed Oct 28, 2021Equity incl. NCI · Q2 FY2022: $4.0B · 10-Q 0000319201-22-000006 filed Jan 28, 2022Equity incl. NCI · Q3 FY2022: $4.1B · 10-Q 0000319201-22-000012 filed Apr 29, 2022Equity incl. NCI · Q4 FY2022: $1.4B · 10-K 0000319201-22-000023 filed Aug 5, 2022Equity incl. NCI · Q1 FY2023: $2.1B · 10-Q 0001628280-22-027311 filed Oct 28, 2022Equity incl. NCI · Q2 FY2023: $2.6B · 10-Q 0000319201-23-000010 filed Jan 27, 2023Equity incl. NCI · Q3 FY2023: $2.7B · 10-Q 0000319201-23-000020 filed Apr 28, 2023Equity incl. NCI · Q4 FY2023: $2.9B · 10-K 0000319201-23-000031 filed Aug 4, 2023Equity incl. NCI · Q1 FY2024: $3.0B · 10-Q 0000319201-23-000039 filed Oct 27, 2023Equity incl. NCI · Q2 FY2024: $3.0B · 10-Q 0000319201-24-000006 filed Jan 26, 2024Equity incl. NCI · Q3 FY2024: $3.1B · 10-Q 0000319201-24-000012 filed Apr 26, 2024Equity incl. NCI · Q4 FY2024: $3.4B · 10-K 0000319201-24-000021 filed Aug 5, 2024Equity incl. NCI · Q1 FY2025: $3.6B · 10-Q 0000319201-24-000027 filed Oct 31, 2024Equity incl. NCI · Q2 FY2025: $3.6B · 10-Q 0000319201-25-000006 filed Jan 31, 2025Equity incl. NCI · Q3 FY2025: $4.0B · 10-Q 0000319201-25-000012 filed May 1, 2025Equity incl. NCI · Q4 FY2025: $4.7B · 10-K 0000319201-25-000024 filed Aug 8, 2025Equity incl. NCI · Q1 FY2026: $5.0B · 10-Q 0000319201-25-000034 filed Oct 31, 2025Equity incl. NCI · Q2 FY2026: $5.5B · 10-Q 0000319201-26-000008 filed Jan 30, 2026Equity incl. NCI · Q3 FY2026: $5.8B · 10-Q 0000319201-26-000016 filed Apr 30, 2026Equity incl. NCI · Q4 FY2026: $6.3B · 10-K 0000319201-26-000027 filed Aug 6, 20264,6926,350294Q1 FY2016Q4 FY2026
$MEquity incl. NCI · Q1 FY2025: $3.6B · 10-Q 0000319201-24-000027 filed Oct 31, 2024Equity incl. NCI · Q2 FY2025: $3.6B · 10-Q 0000319201-25-000006 filed Jan 31, 2025Equity incl. NCI · Q3 FY2025: $4.0B · 10-Q 0000319201-25-000012 filed May 1, 2025Equity incl. NCI · Q4 FY2025: $4.7B · 10-K 0000319201-25-000024 filed Aug 8, 2025Equity incl. NCI · Q1 FY2026: $5.0B · 10-Q 0000319201-25-000034 filed Oct 31, 2025Equity incl. NCI · Q2 FY2026: $5.5B · 10-Q 0000319201-26-000008 filed Jan 30, 2026Equity incl. NCI · Q3 FY2026: $5.8B · 10-Q 0000319201-26-000016 filed Apr 30, 2026Equity incl. NCI · Q4 FY2026: $6.3B · 10-K 0000319201-26-000027 filed Aug 6, 20264,6926,3503,560Q1 FY2025Q4 FY2026Q4 FY2025
Q4 FY2025
4,692$M
All values (44)
PeriodValue ($M)Status
Q4 FY20266,350reported
Q3 FY20265,830reported
Q2 FY20265,466reported
Q1 FY20264,985reported
Q4 FY20254,692reported
Q3 FY20254,005reported
Q2 FY20253,585reported
Q1 FY20253,560reported
Q4 FY20243,368reported
Q3 FY20243,095reported
Q2 FY20243,044reported
Q1 FY20242,990reported
Q4 FY20232,920reported
Q3 FY20232,683reported
Q2 FY20232,603reported
Q1 FY20232,102reported
Q4 FY20221,399reported
Q3 FY20224,079reported
Q2 FY20224,047reported
Q1 FY20223,859reported
Q4 FY20213,376reported
Q3 FY20213,113reported
Q2 FY20212,950reported
Q1 FY20212,762reported
Q4 FY20202,681reported
Q3 FY20202,325reported
Q2 FY20202,688reported
Q1 FY20202,680reported
Q4 FY20192,678reported
Q3 FY20192,886reported
Q2 FY20191,598reported
Q1 FY20191,567reported
Q4 FY20181,621reported
Q3 FY20181,370reported
Q2 FY20181,226reported
Q1 FY20181,464reported
Q4 FY20171,326reported
Q3 FY20171,147reported
Q2 FY2017965reported
Q1 FY2017782reported
Q4 FY2016689reported
Q3 FY2016477reported
Q2 FY2016366reported
Q1 FY2016294reported

CSV with all sources · Technical ID: equity_total

More metrics for KLA

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Gross profit by segment

Sources & calculation
Value
$4.7B
Period
Q4 FY2025, ended Jun 30, 2025 · as of Jun 30, 2025 (balance as of date, not a sum)
Source
10-K, filed Aug 8, 2025 · 0000319201-25-000024
Location
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$4.7BAug 8, 202510-K 0000319201-25-000024reported · confidence 1. · current